Skip to main content

IONS

Stock
Health Care
Biotechnology

Performance overview

IONS Price
Price Chart

Forward-looking statistics

Beta
0.62
Risk
41.33%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Company info

SectorHealth Care
IndustryBiotechnology
Employees923
Market cap$5.7B

Fundamentals

Enterprise value$6.1B
Revenue$717.3M
Revenue per employee—
Profit margin-63.86%
Debt to equity413.80

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.99
Dividend per share—
Revenue per share$4.69
Avg trading volume (30 day)$76M
Avg trading volume (10 day)$98M
Put-call ratio—

Macro factor sensitivity

Growth-2.3
Credit+5.7
Liquidity+2.6
Inflation-5.6
Commodities-1.3
Interest Rates-1.2

Valuation

Dividend yield0.00%
PEG Ratio-11.50
Price to sales9.54
P/E Ratio-11.50
Enterprise Value to Revenue8.52
Price to book14.38

Upcoming events

Next earnings dayApril 30, 2025
Next dividend day—
Ex. dividend day—

News

Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last?

Ionis Pharmaceuticals (IONS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research (July 3, 2025)
Ionis Pharmaceuticals Narrows Q1 Loss, Lifts Revenue Forecast While Drug Sales Surge

Ionis Pharmaceuticals IncĀ IONS reported a first-quarter EPS loss of 93 cents on Wednesday, down from a loss of 98 cents, beating the consensus of a $1.12 loss.

Benzinga (April 30, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free